This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Systemic atrophies primarily affecting CNS in other diseases classified elsewhere달리 분류된 기타 질환에서 일차적으로 중추신경계통을 침범하는 계통적 위축

Contents and key points
ItemDetails
A. Classification codesICD-10: G13.8 | Special Copayment Reduction: V287 (severe intractable disease, 5 years)
B. Synonymssystemic atrophy of the nervous system, secondary central nervous system atrophy; nervous system involvement in other diseases classified elsewhere
C. Adult onsetVery high likelihood of adult onset — the main form is central nervous system atrophy occurring secondary to various adult-onset diseases such as underlying metabolic disease, malignancy, infection, and multiple system atrophy.
1. History19th century: concept of systemic atrophy established → description of systemic nervous diseases such as Charcot-Marie-Tooth → expansion of the concept of secondary CNS atrophy (20th century) → quantification of atrophy with advances in neuroimaging
2. CausesUnderlying metabolic disease (vitamin deficiency, thyroid disease, liver failure), malignancy paraneoplastic syndromes, infection (HIV, prion), toxins (alcohol, heavy metals), autoimmune disease; CNS atrophy secondary to these
3. GeneticsVaries according to the genetic background of the underlying causative disease; some metabolic diseases (Wilson disease, thyroid disease-associated neuropathy) carry a genetic predisposition
4. General epidemiologyG13.8 is a residual ICD-10 code with no precise independent epidemiologic data; related to the epidemiology of the underlying causative disease
5. PathophysiologyMetabolic, toxic, immune, and vascular mechanisms according to the underlying disease → damage to CNS neurons and myelin → progressive systemic atrophy; cerebral cortical, cerebellar, and spinal cord atrophy are the most common forms
6. SymptomsVaries with the underlying disease and site of atrophy; cognitive decline (cortical atrophy), gait ataxia (cerebellar atrophy), muscle weakness and sensory abnormalities (spinal cord atrophy), autonomic abnormalities
7. SignsCerebral, cerebellar, and spinal cord atrophy and white matter signal abnormalities on brain MRI; abnormal neuropsychological testing; specific findings according to the underlying disease
8. ScreeningRegular cognitive and neurological function assessment in persons with an underlying causative disease; follow-up brain MRI; monitoring of metabolic indicators (vitamins, thyroid, etc.)
9. DiagnosisBrain and spinal cord MRI (evaluation of atrophy and signal abnormalities); neuropsychological testing; tests to identify the underlying causative disease; nerve conduction studies and EMG; CSF examination
10. TreatmentTreatment of the underlying causative disease is key (vitamin supplementation, correction of thyroid function, antivirals, immunotherapy); symptomatic treatment (management of cognitive decline, gait aids, physical therapy)
11. PrognosisVaries with treatability of the underlying cause and degree of atrophy; some recovery is possible when reversible causes (vitamin deficiency, thyroid disease) are corrected; progressive atrophy leads to long-term neurological disability
12. PreventionEarly detection and treatment of the underlying causative disease; regular management of metabolic indicators; minimizing exposure to toxins (alcohol, etc.)

1. History

Systemic atrophies primarily affecting the central nervous system in other diseases classified elsewhere (G13.8) is a residual ICD-10 code and collectively refers to CNS atrophy states occurring secondary to various underlying diseases rather than a single disease.

The conceptual history of systemic neural atrophy goes back to the late 19th century. In the 1890s, Charcot, Déjerine, Thomas, and others described primary systemic atrophies such as lateral sclerosis of the spinal cord (ALS) and spinocerebellar ataxia. Secondary systemic CNS atrophy, that is, CNS atrophy due to other systemic diseases, began to be systematized after the mid-20th century.

Subacute combined degeneration of the spinal cord due to vitamin B12 deficiency was described in the late 19th to early 20th century, and the association between pernicious anemia and spinal cord degeneration was established in the 1920s–30s. Various forms of secondary CNS atrophy, such as hepatic myelopathy, cerebellar atrophy due to hypothyroidism, and alcoholic cerebellar degeneration, were described in sequence after the mid-20th century. Advances in neuroimaging (MRI) made it possible to visualize and quantify CNS atrophy in life, expanding the concept of secondary atrophy and providing a tool for follow-up.


2. Causes

The causes of secondary systemic CNS atrophy corresponding to G13.8 are very diverse.

Nutritional deficiency

Vitamin B12 deficiency (pernicious anemia, vegetarianism, malabsorption): posterolateral spinal cord degeneration (subacute combined degeneration). Vitamin E deficiency (fat malabsorption, malnutrition): cerebellar ataxia, sensory neuropathy, spinal cord atrophy. Folate deficiency: cerebral white matter abnormalities. Vitamin B1 (thiamine) deficiency: Wernicke encephalopathy (thalamic atrophy, etc.).

Metabolic disease

Hypothyroidism (severe): cerebellar atrophy, cognitive decline. Hepatic myelopathy (cirrhosis, portal-systemic shunt): lateral column atrophy of the spinal cord. Diabetes-related cognitive decline and central nervous system atrophy.

Toxins and drugs

Alcoholic cerebellar degeneration: cerebellar vermis atrophy. Heavy metal toxicity (mercury, lead, arsenic): multiple system atrophy. Anticancer drugs (cisplatin, taxanes): cerebellar and spinal cord atrophy.

Infection and immunity

HIV-associated neurocognitive disorder (HAND): cerebral atrophy, white matter abnormalities. Creutzfeldt-Jakob disease (CJD, prion): rapid cortical and cerebellar atrophy. Progressive multifocal leukoencephalopathy (PML, JC virus): white matter loss. Hippocampal atrophy after autoimmune encephalitis.


3. Genetics

G13.8 is not a single genetic disease, so there is no direct causative gene. The genetic background depends on the underlying causative disease. Variants in genes for vitamin B12 metabolism-related enzymes (methylmalonyl-CoA mutase, methionine synthase) and transport proteins may increase vulnerability to B12 deficiency. The MTHFR C677T polymorphism is associated with abnormal homocysteine metabolism and related brain atrophy. Wilson disease (ATP7B), genetic predisposition to thyroid disease, and polymorphisms of alcohol metabolizing enzymes (ADH, ALDH) influence the occurrence and progression of related underlying diseases. In prion disease, the PRNP gene (codon 129 polymorphism M/M, M/V, V/V) determines susceptibility to onset and clinical phenotype.


4. General epidemiology

Because G13.8 is a residual ICD-10 code, there are no independent epidemiologic data. Instead, the epidemiology of the main causes is considered. Alcoholic cerebellar degeneration is estimated to occur in about 30–40% of patients with chronic alcohol dependence. Subacute spinal cord degeneration due to vitamin B12 deficiency occurs in about 10–15% of patients with vitamin B12 deficiency. HIV-associated neurocognitive disorder (HAND) occurs in about 15–50% of HIV-infected persons even in the era of ART (antiretroviral therapy). Neurological complications related to hypothyroidism occur not infrequently in patients with untreated severe hypothyroidism. Hepatic myelopathy occurs sporadically in patients with cirrhosis and portal-systemic shunts.


5. Pathophysiology

The pathophysiology differs greatly depending on the underlying cause.

Vitamin deficiency mechanism

Vitamin B12 deficiency: impaired methylmalonyl-CoA metabolism → abnormal fatty acids incorporated into myelin → loss of posterior and lateral spinal cord myelin (subacute combined degeneration). Increased homocysteine → neurotoxicity → brain atrophy. Vitamin E deficiency: antioxidant deficiency → oxidative stress → spinocerebellar degeneration.

Toxin mechanism

Alcoholic cerebellar degeneration: direct toxicity of alcohol to cerebellar Purkinje cells + thiamine deficiency + malnutrition → cerebellar vermis atrophy.

Immune and infection mechanism

HIV-associated atrophy: HIV-infected macrophages and microglia invade the brain → secretion of neurotoxic cytokines (TNF-α, IL-1β) → neuronal apoptosis → cerebral atrophy.


6. Symptoms

Symptoms vary greatly depending on the underlying cause and the CNS structures involved. Cerebellar atrophy (alcoholic, vitamin E deficiency, paraneoplastic): gait ataxia (lower limb predominant), intention tremor, eye movement abnormalities (nystagmus, diplopia), dysarthria (cerebellar dysarthria). Spinal cord atrophy (vitamin B12 deficiency, hepatic myelopathy): lower limb weakness, spasticity, spinal hyperreflexia, positive Babinski, bladder dysfunction, posterior spinal cord symptoms (loss of vibration and position sense). Cortical and subcortical atrophy (alcohol, HIV, prion): cognitive decline (memory, concentration, executive function), behavioral change, personality change, late-stage dementia. Hepatic myelopathy: chronic progressive lower limb spasticity, gait disturbance, bladder dysfunction.


7. Signs

Physical examination confirms reduced cerebellar function (inability to tandem walk, positive Romberg test, limb ataxia, nystagmus), pyramidal signs (spasticity, hyperreflexia, Babinski), posterior spinal cord signs (loss of vibration and position sense), and peripheral neuropathy findings (distal sensory loss, reduced reflexes). Specific findings on brain MRI by cause: cerebellar vermis atrophy (alcoholic), increased T2 spinal cord signal (vitamin B12 deficiency, posterolateral location), thalamic atrophy (Wernicke encephalopathy), generalized cortical atrophy and ventricular enlargement, and white matter signal abnormalities. Reduced cognitive function on neuropsychological testing and abnormal findings on nerve conduction studies and EMG may accompany depending on the underlying disease.


8. Screening

Regular cognitive and neurological function assessment is performed in persons with an underlying causative disease. In patients with chronic alcohol dependence, thiamine, folate, and vitamin B12 status is checked regularly and neurological symptoms are monitored. Serum vitamin B12 is measured regularly in groups at high risk of vitamin B12 deficiency (the elderly, vegetarians, pernicious anemia, after gastrectomy). Regular cognitive function assessment in HIV-infected persons (HAND screening). Monitoring for spinal cord symptoms in patients with cirrhosis. Regular follow-up of thyroid function and assessment of neurological symptoms in patients with hypothyroidism.


9. Diagnosis

Identifying the underlying causative disease comes first. Measure vitamin B12, folate, vitamin E, and thiamine; homocysteine; thyroid function (TSH, free T4); liver function; HIV testing; confirm alcohol use history. Brain and spinal cord MRI: evaluate the distribution of atrophy, sites of signal abnormality, and white matter changes. Confirm that the sites of atrophy are consistent with the underlying cause. Quantify abnormalities in each cognitive domain with neuropsychological testing. Confirm accompanying peripheral nerve abnormalities with nerve conduction studies and EMG. Exclude infectious and immune abnormalities with CSF examination. In systemic CNS atrophy of unknown cause, genetic testing (spinocerebellar atrophy, prion-related PRNP, etc.) is considered.


10. Treatment

Treatment of the underlying causative disease is key. Vitamin B12 deficiency: intravenous vitamin B12 (1,000 μg/day × 1 week, then once weekly × 1 month, then monthly maintenance). Vitamin E deficiency: vitamin E supplementation (high dose in fat malabsorption). Alcoholic neurological injury: alcohol abstinence + thiamine supplementation (100–500 mg/day intravenously for prevention of Wernicke). Hypothyroidism: thyroid hormone replacement. HIV-associated atrophy: viral suppression with effective ART (antiretroviral therapy). Hepatic myelopathy: liver transplantation is the only fundamental treatment; blocking the intrahepatic portal-systemic shunt (TIPS correction) helps in some. Symptomatic treatment: physical therapy (gait aids, balance training), cognitive rehabilitation, use of assistive devices.


11. Prognosis

Prognosis varies greatly depending on the reversibility of the underlying cause and the degree of progression of atrophy. In spinal cord degeneration due to vitamin B12 deficiency, neurological function improves in about 50–70% after supplementation, but complete recovery is difficult for long-standing atrophy. In alcoholic cerebellar degeneration, some functional improvement is possible after abstinence, but permanent atrophy persists. Neurological changes related to hypothyroidism can recover after hormone treatment. HIV-associated atrophy may no longer progress with effective ART, but recovery of already atrophied tissue is limited. Hepatic myelopathy is progressive, and prognosis is poor without liver transplantation.


12. Prevention

There are prevention strategies for each underlying cause. Prevention of nutritional deficiency: sufficient balanced dietary intake, and regular monitoring and supplementation of vitamins B12 and E in high-risk groups (the elderly, vegetarians, patients with malabsorption). Alcohol dependence: support for moderation or abstinence, and prophylactic thiamine supplementation in patients with chronic alcohol dependence. Thyroid disease: early detection and treatment through regular thyroid function tests. HIV prevention: safe sex, not sharing injection needles, pre-exposure prophylaxis (PrEP). Prevention of liver disease: moderation of alcohol intake, prevention and treatment of viral hepatitis, management of cirrhosis complications. In general, early detection and treatment of the underlying cause is the most important prevention strategy for secondary CNS atrophy.


13. References

  1. Kumar N. Neurologic presentations of nutritional deficiencies. Neurol Clin. 2010;28(1):107-170. DOI: 10.1016/j.ncl.2009.09.006. PMID: 19932378.
  2. Victor M, Adams RD, Collins GH. The Wernicke-Korsakoff Syndrome and Related Neurologic Disorders Due to Alcoholism and Malnutrition, 2nd ed. Philadelphia: Davis; 1989.
  3. Greenstein PE, Vonsattel JP, Ropper AH, et al. Acquired hepatocerebral degeneration. J Neurol Neurosurg Psychiatry. 1999;67(5):688-691. DOI: 10.1136/jnnp.67.5.688. PMID: 10519879.
  4. Manto M, Gruol DL, Schmahmann JD, et al. Handbook of the Cerebellum and Cerebellar Disorders. Springer; 2013.
  5. McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol. 2005;4(9):543-555. DOI: 10.1016/S1474-4422(05)70165-4. PMID: 16109361.
  6. Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med. 1988;318(26):1720-1728. DOI: 10.1056/NEJM198806303182604. PMID: 3374544.
  7. Becker PS, Drucker N, Norman D, et al. Neurological complications of immune reconstitution. Lancet Neurol. 2006;5(2):150-162. DOI: 10.1016/S1474-4422(05)00271-8. PMID: 16426990.
  8. Hazell AS, Butterworth RF. Hepatic encephalopathy: An update of pathophysiologic mechanisms. Proc Soc Exp Biol Med. 1999;222(2):99-112. DOI: 10.1177/153537029922200202. PMID: 10564534.
  9. Samuels MA. Metabolic diseases of the nervous system. In: Rowland LP, ed. Merritt's Neurology, 11th ed. Lippincott Williams & Wilkins; 2005.
  10. Mahlknecht P, Hotter A, Hussl A, et al. Significance of MRI in diagnosis and differential diagnosis of Parkinson's disease. Neurodegener Dis. 2010;7(5):300-318. DOI: 10.1159/000314495. PMID: 20460949.